COMMUNIQUÉS West-GlobeNewswire

-
Valneva participera à différentes conférences d’investisseurs aux États-Unis et en Europe au cours du mois de juin
26/05/2025 -
Valneva to Participate at U.S. and European Investor Conferences in June
26/05/2025 -
Transactions under Novonesis’ share buyback program
26/05/2025 -
MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement
26/05/2025 -
Australia Delivers Certainty for US Biotechs in 2025: Avance Clinical Offers Fast Start-Up, Regulatory Predictability, and R&D Rebates
26/05/2025 -
Transactions in Connection with Share Buy-back Program
26/05/2025 -
Brain Cancer Canada Awards $85K to Cutting-Edge Recurrent Glioblastoma Research
26/05/2025 -
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
26/05/2025 -
VIRBAC: Communiqué précisant les modalités de mise à disposition ou de consultation des documents préparatoires à l’assemblée générale mixte ordinaire et extraordinaire
26/05/2025 -
Maple Report: Over Half of Canadian Women Say the Health Care System Fails to Meet Their Needs
26/05/2025 -
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders
26/05/2025 -
Guerbet : Changes in the composition of the Guerbet board of directors.
26/05/2025 -
Guerbet : Evolution de la composition du Conseil d'administration de Guerbet.
26/05/2025 -
ICPO Forum 2025: Advancing Theranostics in Precision Oncology
26/05/2025 -
Chair of Sernova Biotherapeutics Resigns
26/05/2025 -
SpringWorks Therapeutics reçoit un avis favorable du CMUH pour l’utilisation du mirdamétinib pour le traitement des patients adultes et pédiatriques atteints de NF1-PN
25/05/2025 -
ZLNA – Issuance of shares through set-off of option exercise fee
24/05/2025 -
Les données intermédiaires du pétosemtamab de Merus en association avec le pembrolizumab démontrent une réelle efficacité et une bonne durabilité dans le traitement de 1re ligne contre le CETC r/m PD-L1+
24/05/2025 -
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
24/05/2025
Pages